N-Acetyl Semax is a synthetic peptide derivative of ACTH (adrenocorticotropic hormone) that acts as a neuropeptide with cognitive-enhancing and neuroprotective properties. It works by modulating neurotransmitter systems, particularly dopamine and serotonin, and enhancing BDNF (brain-derived neurotrophic factor) expression. Primarily used as a nootropic for cognitive enhancement, focus, and potential treatment of brain fog and cognitive dysfunction.

Overview

N-Acetyl Semax is a modified, potentiated form of Semax (Met-Glu-His-Phe-Pro-Gly-Pro), a synthetic heptapeptide based on the ACTH(4-10) fragment developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Like the parent compound, N-Acetyl Semax incorporates the Pro-Gly-Pro C-terminal extension that confers resistance to proline-specific peptidases. The additional N-acetyl group on the N-terminal methionine further protects against aminopeptidase degradation and may enhance blood-brain barrier penetration, resulting in a more stable and potentially more potent compound. Semax is approved in Russia and several CIS countries as a nootropic and neuroprotective agent for stroke, cognitive disorders, and optic nerve disease, and the N-acetyl derivative represents the next-generation optimization of this clinically validated peptide.

The neuroprotective and cognitive-enhancing effects of N-Acetyl Semax are mediated through multiple converging mechanisms. The compound robustly upregulates brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus, prefrontal cortex, and basal forebrain — regions critical for learning, memory, and executive function. BDNF is the primary neurotrophin responsible for synaptic plasticity, long-term potentiation (LTP), and neurogenesis in the adult brain. Additionally, N-Acetyl Semax modulates melanocortin receptors (MC3R/MC4R), enhances dopaminergic and serotonergic neurotransmission, upregulates nerve growth factor (NGF) and glial cell-derived neurotrophic factor (GDNF), and activates the CREB transcription factor pathway — a master regulator of memory-related gene expression. In stroke and ischemia research, Semax has demonstrated significant neuroprotection through anti-inflammatory effects, reduction of oxidative stress, prevention of apoptosis, and modulation of gene expression patterns associated with neural repair.

N-Acetyl Semax is typically administered intranasally at doses of 200–600 mcg per nostril, 1–3 times daily, with the nasal route providing rapid access to the central nervous system via olfactory and trigeminal nerve pathways. Users commonly report improved focus, mental clarity, verbal fluency, and mood elevation, with effects noticeable within 15–30 minutes and lasting several hours. The compound is frequently paired with N-Acetyl Selank for a balanced nootropic protocol — Semax provides stimulatory, dopaminergic, and cognitive-enhancing effects while Selank contributes anxiolytic and GABAergic modulation, creating a synergy that enhances cognition without excessive stimulation or anxiety. In broader nootropic stacks, N-Acetyl Semax is combined with cholinergic compounds like alpha-GPC, racetams, and lion's mane for comprehensive neuroplasticity support. Side effects are minimal and may include mild nasal irritation, headache, or transient dizziness.

Mechanism of Action

Structural Basis

N-Acetyl Semax is the N-terminally acetylated form of Semax. Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment with a C-terminal Pro-Gly-Pro stabilizing extension, developed at the Institute of Molecular Genetics, Russian Academy of Sciences. The N-acetyl group confers resistance to aminopeptidase degradation, improving metabolic stability and duration of action. Unlike ACTH itself, Semax and N-Acetyl Semax lack adrenocortical stimulatory activity — they do not increase cortisol.

Neurotrophin Upregulation

The most well-characterized mechanism of N-Acetyl Semax is its robust upregulation of neurotrophins. It increases mRNA and protein levels of BDNF, NGF, and NT-3 in the hippocampus, cortex, and basal forebrain. BDNF/TrkB activation drives MAPK/ERK, PI3K/Akt/mTOR, and PLCγ/CaMKII pathways that strengthen long-term potentiation (LTP), promote dendritic spine remodeling, and stimulate adult hippocampal neurogenesis. The magnitude of BDNF upregulation reported for Semax (1.4-2x fold increase in hippocampal BDNF mRNA) is among the most potent for any peptide nootropic.

Melanocortin System

As an ACTH(4-10) analog, N-Acetyl Semax retains affinity for melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors in the CNS. MC4R activation in the hippocampus and cortex stimulates adenylyl cyclase/cAMP/PKA and ERK signaling, modulating attention, memory consolidation, and motivation. This melanocortinergic activity is dissociated from the MC2R-mediated adrenal effects of full-length ACTH, allowing cognitive benefits without cortisol elevation.

Monoamine & Cognitive Effects

N-Acetyl Semax modulates dopamine and serotonin systems by increasing tyrosine hydroxylase (TH) and tryptophan hydroxylase (TPH) expression and modulating monoamine transporter activity. Increased dopaminergic transmission in the prefrontal cortex enhances working memory and executive function, while serotonergic modulation in limbic structures contributes to emotional regulation and stress resilience.

Neuroprotection in Ischemia

Semax is clinically approved in Russia for ischemic stroke treatment. Its neuroprotective mechanism involves suppression of microglial activation and inflammatory cytokine release (IL-1beta, TNF-alpha), reduction of glutamate excitotoxicity, stabilization of the blood-brain barrier, and promotion of neurovascular unit survival through BDNF-TrkB and VEGF signaling. Gene expression profiling in ischemic brain tissue shows modulation of over 1,000 genes related to inflammation, apoptosis, and neuroplasticity.

Reconstitution Calculator

Research

Safety Profile

Commonly reported side effects include potential hair loss, headaches, and nasal irritation if used as a spray, with increased anxiety or mood changes being less common. It is contraindicated for individuals with a history of seizures, severe psychiatric disorders, or hypersensitivity, and should be avoided during pregnancy. It has limited long-term human safety data, and caution is advised when combining it with other medications affecting neurotransmitters.

Pharmacokinetic Profile